Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA
Serum hepatitis B surface antigen (HBsAg) level < 100 IU/ml and undetectable hepatitis B virus (HBV) DNA have been recently proposed as an alternate endpoint of "partial cure" in chronic hepatitis B (CHB). We investigated clinical outcomes of hepatitis B e antigen (HBeAg)-negative CHB patients with HBsAg <100 IU/ml and undetectable HBV DNA. Treatment-naïve HBeAg-negative CHB patients with undetectable HBV DNA and normal alanine aminotransferase were retrospectively included from three institutions. Patients were classified into the low HBsAg group (<100 IU/ml) and the high HBsAg group (≥100 IU/ml). Liver fibrosis was evaluated by noninvasive tests (NITs). A total of 1218 patients were included and the median age was 41.5 years. Patients with low HBsAg were older (45.0 vs. 40.0 years, P < 0.001) than those in the high HBsAg group, while the NIT parameters were comparable between groups. During a median follow-up of 25.7 months, patients with low HBsAg achieved a higher HBsAg clearance rate (13.0% vs. 0%, P < 0.001) and a lower rate of significant fibrosis development (2.2% vs. 7.0%, P = 0.049) compared to patients with high HBsAg. No patient developed HCC in either group. HBsAg level was negatively associated with HBsAg clearance (HR 0.213, P < 0.001) and patients with HBsAg < 100 IU/ml had a low risk of significant fibrosis development (HR 0.010, P = 0.002). The optimal cutoff value of HBsAg for predicting HBsAg clearance was 1.1 Log10 IU/ml. Treatment-naïve HBeAg-negative CHB patients with HBsAg <100 IU/ml and undetectable HBV DNA had favourable outcomes with a high rate of HBsAg clearance and a low risk of fibrosis progression.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Emerging microbes & infections - 13(2024), 1 vom: 08. Apr., Seite 2339944 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Jian [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antiviral Agents |
---|
Anmerkungen: |
Date Completed 18.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/22221751.2024.2339944 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM37073999X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM37073999X | ||
003 | DE-627 | ||
005 | 20240425233547.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240408s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/22221751.2024.2339944 |2 doi | |
028 | 5 | 2 | |a pubmed24n1386.xml |
035 | |a (DE-627)NLM37073999X | ||
035 | |a (NLM)38584592 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wang, Jian |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.04.2024 | ||
500 | |a Date Revised 25.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Serum hepatitis B surface antigen (HBsAg) level < 100 IU/ml and undetectable hepatitis B virus (HBV) DNA have been recently proposed as an alternate endpoint of "partial cure" in chronic hepatitis B (CHB). We investigated clinical outcomes of hepatitis B e antigen (HBeAg)-negative CHB patients with HBsAg <100 IU/ml and undetectable HBV DNA. Treatment-naïve HBeAg-negative CHB patients with undetectable HBV DNA and normal alanine aminotransferase were retrospectively included from three institutions. Patients were classified into the low HBsAg group (<100 IU/ml) and the high HBsAg group (≥100 IU/ml). Liver fibrosis was evaluated by noninvasive tests (NITs). A total of 1218 patients were included and the median age was 41.5 years. Patients with low HBsAg were older (45.0 vs. 40.0 years, P < 0.001) than those in the high HBsAg group, while the NIT parameters were comparable between groups. During a median follow-up of 25.7 months, patients with low HBsAg achieved a higher HBsAg clearance rate (13.0% vs. 0%, P < 0.001) and a lower rate of significant fibrosis development (2.2% vs. 7.0%, P = 0.049) compared to patients with high HBsAg. No patient developed HCC in either group. HBsAg level was negatively associated with HBsAg clearance (HR 0.213, P < 0.001) and patients with HBsAg < 100 IU/ml had a low risk of significant fibrosis development (HR 0.010, P = 0.002). The optimal cutoff value of HBsAg for predicting HBsAg clearance was 1.1 Log10 IU/ml. Treatment-naïve HBeAg-negative CHB patients with HBsAg <100 IU/ml and undetectable HBV DNA had favourable outcomes with a high rate of HBsAg clearance and a low risk of fibrosis progression | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Chronic hepatitis B | |
650 | 4 | |a HBsAg clearance | |
650 | 4 | |a hepatitis B surface antigen | |
650 | 4 | |a liver fibrosis | |
650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
650 | 7 | |a Hepatitis B e Antigens |2 NLM | |
650 | 7 | |a DNA, Viral |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
700 | 1 | |a Zhu, Li |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Shaoqiu |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Zhiyi |e verfasserin |4 aut | |
700 | 1 | |a Fan, Tao |e verfasserin |4 aut | |
700 | 1 | |a Cao, Fei |e verfasserin |4 aut | |
700 | 1 | |a Xiong, Ye |e verfasserin |4 aut | |
700 | 1 | |a Pan, Yifan |e verfasserin |4 aut | |
700 | 1 | |a Li, Yuanyuan |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Chao |e verfasserin |4 aut | |
700 | 1 | |a Yin, Shengxia |e verfasserin |4 aut | |
700 | 1 | |a Tong, Xin |e verfasserin |4 aut | |
700 | 1 | |a Xiong, Yali |e verfasserin |4 aut | |
700 | 1 | |a Xia, Juan |e verfasserin |4 aut | |
700 | 1 | |a Yan, Xiaomin |e verfasserin |4 aut | |
700 | 1 | |a Liu, Yong |e verfasserin |4 aut | |
700 | 1 | |a Liu, Xingxiang |e verfasserin |4 aut | |
700 | 1 | |a Chen, Yuxin |e verfasserin |4 aut | |
700 | 1 | |a Li, Jie |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Chuanwu |e verfasserin |4 aut | |
700 | 1 | |a Wu, Chao |e verfasserin |4 aut | |
700 | 1 | |a Huang, Rui |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Emerging microbes & infections |d 2012 |g 13(2024), 1 vom: 08. Apr., Seite 2339944 |w (DE-627)NLM249608804 |x 2222-1751 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2024 |g number:1 |g day:08 |g month:04 |g pages:2339944 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/22221751.2024.2339944 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2024 |e 1 |b 08 |c 04 |h 2339944 |